Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?
IntroductionThere is a lack of real-world evidence regarding the impact of concomitant metformin and renin-angiotensin system inhibitors (RASis) on sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated kidney outcomes. This study was aimed to investigate whether SGLT2i-associated kidney outco...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2024-06-01
|
| Reeks: | Frontiers in Endocrinology |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1329945/full |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|